How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs
  
Delays at the FDA could preclude acquisitions by big pharma, but drive biotechs to merge. (Shutterstock/AI generated)

More from US FDA

More from Podcasts